Načítá se...
Entry inhibitors: New advances in HCV treatment
Hepatitis C virus (HCV) infection affects approximately 3% of the world's population and causes chronic liver diseases, including liver fibrosis, cirrhosis, and hepatocellular carcinoma. Although current antiviral therapy comprising direct-acting antivirals (DAAs) can achieve a quite satisfying...
Uloženo v:
| Vydáno v: | Emerg Microbes Infect |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4735057/ https://ncbi.nlm.nih.gov/pubmed/26733381 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/emi.2016.3 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|